Metformina Stadafarma (Metformin Hydrochloride)

Metformin primarily activates AMP‑activated protein kinase (AMPK) in liver and muscle cells. This activation suppresses gluconeogenesis in the liver, reduces intestinal glucose absorption, and enhances peripheral glucose uptake, leading to lower fasting and post‑prandial blood glucose levels without directly stimulating insulin secretion.

The dosage of Metformina Stadafarma is individualized by the prescribing clinician. Typically, treatment starts with a low dose to improve tolerability and is gradually titrated based on the patient’s glycaemic response, renal function, and side‑effect profile. Exact dosing regimens should follow the prescriber’s instructions.

Safety data for metformin in pregnancy and lactation are limited. It may be used during pregnancy only if the potential therapeutic benefit outweighs possible risks, and under close medical supervision. Metformin is excreted in breast milk in small amounts; breastfeeding mothers should discuss continuation with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Metformina Stadafarma (metformin) differs from sulfonylureas, which stimulate insulin release and carry a higher hypoglycaemia risk. Compared with newer classes such as SGLT2 inhibitors or GLP‑1 receptor agonists, metformin is weight‑neutral, inexpensive, and has a long safety record, though it lacks the cardiovascular benefits observed with some newer agents.

Store Metformina Stadafarma at ambient temperature, below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat, and direct sunlight. Do not store in the bathroom or near a kitchen sink where humidity is high.

Metformina Stadafarma is taken orally, usually with meals to minimise gastrointestinal upset. Tablets should be swallowed whole with a full glass of water. The exact timing and frequency are determined by the prescribing clinician based on individual therapeutic goals.

The most serious adverse events are lactic acidosis—a rare but potentially fatal metabolic disturbance—and severe hypoglycaemia when metformin is combined with insulin or sulfonylureas. Prompt medical attention is required if patients experience unexplained muscle pain, rapid breathing, abdominal discomfort, or signs of low blood sugar.

Metformina Stadafarma is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those receiving iodinated contrast studies without adequate renal monitoring. Clinicians should evaluate each patient’s medical history before initiating therapy.